Zentalis
2 known investors
Zentalis is a clinical-stage pharmaceutical company developing azenosertib, an investigational oral therapy that inhibits WEE1 kinase to disrupt the cell-cycle safeguards cancer cells use to survive. It focuses on providing physicians and patients with a targeted, non-chemotherapy oral treatment option in oncology.
BiotechHealthtech
Investors · 2
Frequently asked questions
- What does Zentalis do?
- Zentalis is a clinical-stage pharmaceutical company developing azenosertib, an investigational oral therapy that inhibits WEE1 kinase to disrupt the cell-cycle safeguards cancer cells use to survive. It focuses on providing physicians and patients with a targeted, non-chemotherapy oral treatment option in oncology.
- Who are Zentalis's investors?
- Zentalis's investors include Decheng Capital, Highlight Capital.